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Purpose: Mutations in ELOVL4, a member of the fatty acid elongase (ELO) family, are responsible for autosomal domi­
nant Stargardt-like macular degeneration. The specific role of ELOVL4 in photoreceptors and the degenerative events 
induced by dominant ELOVL4 mutations are not well understood. As a first step to identifying possible mechanisms 
contributing to cellular dysfunction, we transfected HEK293 and COS cells with fluorescent-labeled wild-type and m u­
tant ELOVL4 constructs. Effects of mutant ELOVL4 on interaction with wild-type protein were examined in this in vitro 
model.
M ethods: Wild-type and mutant ELOVL4 proteins including ELOVL4 truncation (270X, a truncated ELOVL4 protein at 
amino acid position 270) and ELOVL4 5 bp deletion (5bp-del) and ELOVL4 (5A, substituting the ER retention signal,
KAKGD, with a five alanine amino acid tract) were expressed as EGFP or DsRed fusion proteins. Cellular localization of 
these proteins was examined by fluorescence microscopy, ELOVL4 protein aggregates were measured by co-immunopre- 
cipitation and by sucrose gradient centrifugation followed by immunodetection with western blots. To study cellular 
status of cells expressing mutant ELOVL4 proteins, transfected cells were examined for upregulation of Bip and CHOP, 
markers for the unfolded protein response (UPR) by western blotting,
Results: ELOVL4 mutants were not retained within the ER but were rather mislocalized and formed aggregates, Impor­
tantly, when cotransfected with wild-type ELOVL4, the mutants bound to and sequestered the wild-type protein into the 
aggregates, Expression of ELOVL4 mutants also induced UPR as evidenced by Bip and CHOP expression,
Conclusions: Using this in vitro cell system, we have identified alterations in wild-type ELOVL4 protein localization, 
aggregate formation, and the induction of cellular stress by the ELOVL4 mutants, We propose that “inactivation” of the 
wild-type ELOVL4 protein through sequestration to a non-ER compartment by ELOVL4 mutants may play a role in 
cellular dysfunction,
Stargardt-like macular degeneration (STGD3; OMIM 
600110) is an autosomal dominant form of juvenile macular 
degeneration characterized by decreased visual acuity, macu­
lar atrophy, and extensive flecks [1,2], The disease shares some 
similarity with age-related macular degeneration (AMD), the 
leading cause of legal blindness in the elderly in developed 
countries, including abnormal accumulation of lipofuscin in 
the retinal pigment epithelium (RPE) and degeneration of RPE 
and m acular photoreceptors, The disease-causing gene, 
ELOVL4, has been identified, however the function of the 
encoded protein is not known, nor is it understood why the 
retina is uniquely sensitive to disease-causing mutations in 
this gene, ELOVL4 encodes a 314 amino acid protein with 
sequence and structural similarities to the ELO family of pro­
teins [3], The ELO family of proteins is involved in the elon­
gation of long chain fatty acids and is characterized by mul­
tiple putative membrane-spanning domains, a histidine clus­
ter motif (HXXHH) essential for the enzymatic activity [4,5],
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and an ER retention signal (KXKXX) [6], Therefore, based 
on similarities of ELOVL4 gene structure to the ELO family, 
it has been proposed that the protein may play a role in fatty 
acid elongation within the ER [7-10], The importance of this 
protein is underscored by the fact that ELOVL4 is strongly 
conserved throughout vertebrate species [11,12],
Three ELO VL4  mutations causing juvenile macular de­
generation have been identified thus far, The first mutation is 
a five base pair deletion starting at position 790 of the open 
reading frame (790-794delAACTT, 5bp-del) [3] causing a 
frame-shift and a premature stop codon, The second mutation 
contains two 1 base pair deletions, 789delT and 794delT [13], 
which produces a frame-shift nearly identical to the five base 
pair deletion, We recently reported the third mutation, a trans­
version of C->G at position 810 causing a stop codon at amino 
acid 270 (270X) [14], Interestingly, all three mutations occur 
around the same location and subsequent deletion of the C- 
terminus includes loss of the putative dilysine ER retention 
signal,
These ELOVL4 mutations induce a dominant effect over 
the wild-type allele resulting in Stargardt macular dystrophy, 
Previous studies demonstrated that unlike wild-type ELOVL4, 
the mutants do not localize to the ER [9,10], Although no his­
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topathologic studies on postmortem specimens of affected 
STGD3 patients have been reported, our recent results dem­
onstrate lipofuscin  accum ulation, e lectrophysiological 
changes, and photoreceptor degeneration in mutant ELO VL4  
transgenic mice in a manner that is closely related to the hu­
man phenotype [15], In this study, we co-expressed mutant 
and wild-type ELOVL4 proteins in cell culture and examined 
effects of the mutant over the wild-type protein with respect 
to cellular localization, We demonstrate that mutant ELOVL4 
altered proper ER localization of wild-type ELOVL4 and se­
questered the wild-type and mutant proteins into dense aggre­
gates,
Aggregated, misfolded proteins have been shown to bind 
chaperones and activate the unfolded protein response (UPR) 
[16-18], Based on formation of aggregates, we assessed ef­
fects of these mutants on induction of the UPR, ER stress was 
measured by altered expression of the resident ER molecular 
chaperones, Bip and CHOP [16], We demonstrate that expres­
sion of mutant ELOVL4 led to activation of the UPR and sub­
sequent ER stress,
M ETHODS
Reagents: Cell culture and transfection reagents were pur­
chased from  G ibco-B R L (Inv itrogen , C arlsbad, CA),
Polyclonal and monoclonal anti-EGFP antibodies and poly L- 
lysine were purchased from Sigma (Sigma Chemical Co,, St, 
Louis, MO), Anti-DsRed monoclonal antibody and the ER 
specific marker pDsRed2-ER were purchased from Clontech, 
Bip (Clontech, Mountain View, CA), CHOP, and P-actin anti­
bodies and Protein A/G plus agarose were purchased from 
Santa Cruz (Santa Cruz Biotech, Santa Cruz, CA), Chamber 
slides were purchased from Nunc (Nalge, Rochester, NY), 
Generation o f  expression constructs: All vectors used in 
this study utilized a CMV promoter and expressed enhanced 
green fluorescent protein (EGFP) or DsRed/ELOVL4 fusion 
proteins, Construction of wild-type, 5 bp deletion, and 270X 
mutant ELO VL4  expression vectors have been described else­
where [9,14], Briefly, forward and reverse primers (5'-CGC 
GGA TCC GCG ATG GGG CTC CTG GAC TC-3' and 5'- 
CGG GAT CCC GTT AAG CTG CTG CTG CTG CTC CAT 
TTT TCT GCT TTT TTC-3', incorporating K pnI and Bam HI 
restriction sites) were used to amplify wild-type ELO VL4  
cDNA, The resultant PCR products were digested and cloned 
into the KpnI and Bam HI sites in the pEGFPC1 vector pur­
chased from Clontech (Clontech, Mountain View, CA), DsRed 
fusion constructs were generated by amplification of ELOVL4 
using forward and reverse primers (5'-CAT GCC ATG GCC 
TCC TCC GAG AAG GTC-3’and 5'-GGG GTA CCC AGG
B
pCMV EGFP wtELOVL4 pA
r*
^KGD/AAAA£
pCMV EGFR mtELOVL4 (5A) I PA
r*
pCMV DsRed2 wtE LO VL4 PA
pCMV DsRed2 mtELQVL4(5bp^ el) pA
r*




Figure 1, Nomenclature and diagrams of recombinant ELOVL4 constructs, A: EGFP and wild-type ELOVL4 fusion protein (wtEGFP/ 
ELOVL4), B: EGFP fusion protein with the ER retention signal, KAKGD, replaced by AAAAA (mtEGFP/ELOVL4(5A)), C: DsRed2 and 
wild-type ELOVL4 fusion protein (wtDsRed/ELOVL4), D: DsRed2 and 5 bp deleted ELOVL4 mutant fusion protein (mtDsRed/ELOVL4(5bp- 
del)), E: DsRed2 and 270X ELOVL4 mutant fusion protein (mtDsRed/ELOVL4 (270X)) F: DsRed2 fusion protein with C-terminal ER 
retention signal, KAKGD, replaced with AAAAA (mtDsRed/ELOVL4(5A)), pCMV represents immediate early promoter from cytomega­
lovirus; EGFP represents enhanced green fluorescent protein; DsRed represents red fluorescent protein; pA represents polyadenylation signal 
from SV40 T-antigen; KAKGD/AAAAA represents dilysine motif replaced with alanine tract, All fluorescent proteins were fused in frame at 
the N-terminal end of the wild-type or mutant ELOVL4 amino acid sequence,
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AAC AGG TGG TGG CGG C-3)’ containing NcoI and KpnI 
for insertion into the DsRed2 vector. Vector constructs and 
fusion proteins bearing a mutant amino acid sequence are des­
ignated with an “mt” prefix, while the wild-type counterparts 
bear a “wt” prefix. mtDsRed/ELOVL4(5bp-del), mtDsRed/ 
ELOVL4(270X), and mtDsRed/ELOVL4(5A) were derived 
by in vitro mutagenesis as described in previous reports [9,14]. 
All recombinant plasmids were verified by DNA sequencing. 
A cartoon representation of the constructs and proteins is shown 
in Figure 1 illustrating the nomenclature of the fusion pro­
teins used in the present experiments.
Transfection studies and image acquisition: COS-7 and 
HEK293 were used for all transfection studies. Details of trans­
fection, fluorescence microscopy, and confocal microscopy 
have been described previously [9]. Briefly, cells were trans­
fected at 50-60% confluence in 60 mm plates with 5 ^g of 
respective recombinant DNAs using lipofectamine reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocol. Recombinant protein expression was assayed at 24 
h after transfection. To assess progressive expression of wild- 
type and mutant ELOVL4 proteins, transfected cells were ex­
amined by fluorescence microscopy at daily intervals post­
transfection. No variability was noted and the data presented 
in this study were collected after approximately 24 h. Co-trans­
fections with the ER specific marker pDsRed2-ER (Clontech, 
M ountain View, CA) were performed with wild-type and 
mutant ELOVL4 constructs to determine the subcellular lo­
calization of ELOVL4 proteins.
Immunoprecipitation: To investigate the interaction of 
wild-type EGFP/ELOVL4 and mutant DsRed/ELOVL4, co- 
immunoprecipitation experiments were conducted. Cells were 
first co-transfected with wtEGFP/ELOVL4 and mtDsRed/ 
ELOVL4(5bp-del) recombinant fusion proteins and expres­
sion examined by fluorescence microscopy. Cells were col­
lected 24 h after transfection and washed with PBS. Cell ly­
sates were prepared with immunoprecipitation buffer (1% (v/ 
v) Triton X-100 in 50 mM Tris-HCl buffer (pH 7.4), 0.15 M 
NaCl, 1 mM EDTA, and 0.1% (w/v) SDS containing protease 
inhibitor cocktail, Sigma). The polyclonal anti-EGFP antibody 
(2 ^g of antibody per 1 ml reaction mixture containing 30 ^l 
of Protein A/G agarose) was used for immunoprecipitation 
and proteins were separated by SDS-PAGE. A monoclonal anti- 
DsRed antibody (Clontech, Mountain View, CA) was used 
for western blot analysis.
Sucrose density gradient sedimentation: To investigate 
the interaction and aggregation of wild-type EGFP/ELOVL4 
and mutant DsRed/ELOVL4, sucrose gradient sedimentation 
velocity experiments were conducted. HEK293 cells were 
co tran sfec ted  w ith  w tE G FP/E L O V L 4 and m tE G FP/ 
ELOVL4(5bp-del), m tEGFP/ELOVL4(5A), or mtEGFP/ 
ELOVL4(5bp-del) constructs. Cells were extracted in 10 mM 
Tris-HCl, pH 7.5, 0.25% Triton X-100, 2 ^M  digitonin, and 
protease inhibitors 24 h after transfection, and centrifuged at 
4 °C for 30 min at 13,000x g. The supernatant (200 ^l) was 
diluted with 50 mM sucrose in 5 mM HEPES (pH 7.2)/0.2 
mM EDTA to a final volume of 300 ^l and centrifuged on a 5 
ml 5-20% (w/v) sucrose gradient for 18 h at 180,000x g in an
SW50.1 rotor (Beckman Coulter, Fullerton, CA) [19]. Sucrose 
density gradient sedimentation was used to separate ELOVL4 
and ELOVL4 aggregates based on expected differences in 
molecular weight and additional physiochemical properties. 
Therefore, higher molecular weight ELOVL4 aggregates are 
easily  sep ara ted  from  the low er m o lecu la r w eight, 
unaggregated ELOVL4 protein. To identify altered ELOVL4 
sedimentation characteristics, 200 ^l fractions and the pellet 
were collected and analyzed by western blotting.
Immunoblotting: For western analysis of Bip and CHOP 
proteins, the membranes were incubated overnight with anti- 
Bip and anti-CHOP (1:500) and (3-actin antibodies (1:2000), 
and then probed with peroxidase-conjugated secondary anti­
bodies (Amersham Biosciences Corp., Piscataway, NJ). An 
ECL detection kit (Amersham) was used according to the 
manufacturer’s protocol. Tunicamycin exposure is known to 
up regu la te  CHOP in ce ll cu ltu res [20] and, as such, 
tunicamycin treatment was used as a positive control for UPR 
induction. Cells were transfected with vector alone and treated 
with 10 or 20 ^g/ml tunicamycin for 4 h at 37 °C, cells were 
harvested, and cell lysates used for western blot analysis.
RESULTS
Characterization o f  EG FP-ELO VL4 fu sion  proteins: Since 
an ELOVL4 antibody was not available for these studies we 
generated fluorescent ELOVL4 fusion proteins. Wild-type and 
mutant ELOVL4 were expressed as EGFP and DsRed fusion 
proteins (Figure 1 and [9]) to facilitate direct visualization. 
Similar results were obtained by Grayson et al. [21] using an 
ELOVL4/RIM epitope fusion protein. Furthermore, consis­
tent with presence of a dilysine ER retention motif at the C- 
terminus of the protein, the ELOVL4/EGFP fusion protein 
colocalized with the ER specific marker, pDsRed2-ER (Fig­
ure 2B). Western blot analysis confirmed the synthesis of all 
ELOVL4 fusion proteins and single bands were visualized for 
each construct and shown in Figure 3 and Figure 4. Culture 
medium was examined by western blot analyses; no detect­
able protein was found (data not shown). Similar observations 
were found in both HEK293 and COS-7 cells. Wild-type 
ELOVL4 constructs were localized to the ER, and mutant 
ELOVL4 constructs were mislocalized as in our previous re­
sults [9], indicated by loss of co-fluorescent signal with the 
ER specific marker, pDsRed2-ER, (Figure 2B).
D om inant effect o f  m utant ELOVL4: Wild-type EGFP/ 
ELOVL4 and mutant DsRed/ELOVL4 were co-expressed to 
examine effects of the mutant protein on wild-type cellular 
localization. Co-transfection of wild-type ELOVL4 constructs 
(EGFP/ELOVL4 and DsRed2/ELOVL4) showed a more dif­
fuse cytoplasmic co-localized signal (Figure 2A, first row) 
residing predom inantly within the ER as shown by co- 
immunolabeling with DsRed2-ER (Figure 2B). In all cells 
showing coexpression of the mutant (mtDsRed/ELOVL4(5bp- 
del), mtDsRed/ELOVL4(270X), or mtDsRed/ELOVL4(5A)) 
and wild-type proteins, immunolabeled proteins were co-lo­
calized in densely clumped aggregates (Figure 2A, arrows), 
which, upon co-expression of the DsRed2-ER marker, revealed 
loss of ER localization (Figure 2B). These results suggested 
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Figure 2. Localization of transfected ELOVL4 fusion proteins. Confocal images were recorded 24 h after transfection. A: wtEGFP/ELOVL4 
was cotransfected (1:1) with wtDsRed/ELOVL4 or mutant DsRed/ELOVL4 constructs as indicated in each panel. The green color represents 
EGFP fused ELOVL4 wild-type protein, and the red color identifies the wild-type or mutant DsRed fused ELOVL4 proteins. When wild-type 
and mutant proteins were co-expressed, the overlapping (yellow) fluorescence signals were associated with aggregates (right panels). Note the 
clumped signals (both EGFP and DsRed) in the cells co-expressing mutant ELOVL4 protein (arrows). B: To visualize mislocalized ELOVL4 
proteins, recombinant wtEGFP/ELOVL4 and mutant EGFP/ELOVL4 constructs were cotransfected with the ER specific marker, pDsRed2- 
ER. M utant ELOVL4 protein signals (green) did not overlap with the ER protein marker signal (red).
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that the mutant protein, showing loss of ER retention, could 
similarly affect normal distribution of the wild-type ELOVL4 
protein,
Since the Stargardt mutations include deleted residues out­
side the ER retention domain, we wished to test whether the 
loss of this ER domain was responsible for altered protein 
localization, Therefore, the C-terminal ER retention domain 
was replaced with a tract of five alanines (and the mutant was 
named “5A”). We found a similar subcellular mislocalization 
between mtDsRed/ELOVL4(5A) and the other pathogenic 
mutants where there was no co-localization with an ER spe­
cific marker, pDsRed2-ER, This suggested that this shoprt 
domain was sufficient for mislocalization and, in coexpression 
assays, altered the normal ER localization of the wild-type 
protein,
In terac tion  o f  w ild -type and  m u tan t E LO V L4: The 
wtEGFP/ELOVL4 and mtDsRed/ELOVL4(5bp-del) proteins 
were co-expressed and co-immunoprecipitated with the EGFP 
antibody, The co-immunoprecipitated mutant proteins were 
subsequently identified by western blot using the DsRed anti­
body (Figure 3). Grayson et al. [21] recently reported similar 
results using an affinity column binding assay, but contrary to 
our results showed that wild-type ELOVL4 can associate with 
wild-type ELOVL4 protein. Using immunoprecipitation in this 
study, we saw no significant intramolecular association of the 
wild-type protein, This may have been due to less sensitivity
IP: anti-EGFP WB: anti-EGFP 
WB: anti-DsRed +anti-DsRed
81­
__ m ^_wt EGFP/EL0VL4
5 0 -  mt DsRed/EL0VL4 (5bp-del)
3 0 -
Figure 3, Western blots of co-immunoprecipitated wild-type and 
m utant ELOVL4, The EGFP antibody was used to precipitate 
wtEGFP/ELOVL4 and mutant ELOVL4 protein complexes, A DsRed 
monoclonal antibody was used for immunodetection of mtDsRed/ 
ELOVL4 proteins, Lane 1: The EGFP antibody (specific for the 
wtEGFP/ELOVL4 protein construct) co-immunoprecipitated the 
mtDsRed/ELOVL4(5bp-del) protein, Lane 2: Untransfected control, 
Lane 3: Control showing expression of both proteins wtEGFP/ 
ELOVL4 (upper band, about 63 kDa) and mtDsRed/ELOVL4(5bp- 
del, lower band, about 53 kDa) with co-transfection, IP represents 
immunoprecipitation; WB represents western blot; anti-EGFP rep­
resents antibody to enhanced green fluorescent protein; anti-DsRed 
represents antibody to red fluorescent protein; wt EGFP/ELOVL4 
represents fusion protein containing the enhanced green fluorescent 
protein fused in frame to the N-terminal end of wildtype ELOVL4 
protein; mtDsRed/ELOVL4(5bp-del); fusion protein containing the 
red fluorescent protein fused in frame at the N-terminal end of a 
mutant (C-terminal 5bp deletion) ELOVL4 protein.
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using immunoprecipitation, However, we also saw no obvi­
ous aggregate formation in wild-type ELOVL4 transfection 
studies, suggesting that wild-type ELOVL4 protein interac­
tions are not as extensive as that with the mutant ELOVL4 
protein, This result demonstrates that the mutant and wild- 
type proteins associate when co-expressed,
To further demonstrate association of the wild-type and 
mutant ELOVL4 proteins (over that of wild-type alone), trans­
fected cell lysates were separated on sucrose gradients, frac­
tions were collected, electrophoresed, and immunolabeled on 
western blots. The wild-type protein sedimented with the lower 
molecular weight protein fractions (fraction numbers 15-18 
in Figure 4). Conversely, MtDsRed/ELOVL4(5bp-del) and 
mtEGFP/ELOVL4(5A) formed high molecular weight aggre­
gates (Figure 4). When coexpressed with mutant ELOVL4, 
the wild-type protein shifts to the higher molecular weight 
fractions (fraction numbers 1-10 in Figure 4A) similar to trans­
fection of mutant ELOVL4 alone. These results suggest that 
wild-type and mutant proteins are in fact colocalized in cell 
aggregates, In addition, the ELOVL4(5A) mutant mimics the 
other ELOVL4 mutants (data not shown) in forming and se­
questering wild-type ELOVL4 within higher molecular weight 
aggregates, thereby altering the proper localization of wild- 
type ELOVL4 proteins.
Induction o f  UPR associated proteins by m utant ELOVL4: 
The mutant ELOVL4 aggregates suggested that the mutant 
proteins may be misfolded, It is known that when ER is ex­
posed to m isfolded/unfolded proteins, cells respond by 
upregulating ER chaperones such as Bip/Grp78 and Grp94, 
and CHOP via the ER-kinase, PERK [22,23]. To investigate 
the involvement of a UPR to mutant ELOVL4 expression, we 
examined transfected cells for Bip and CHOP upregulation. 
We found that both Bip and CHOP protein levels were mark­
edly increased by transfection of the mutant ELOVL4 (Figure 
5B,C). These results were similar to that of the tunicamycin- 
treated group as a positive control for UPR activation (Figure 
5E), Thus, mutant ELOVL4 protein-induced upregulation of 
the UPR proteins Bip and CHOP may initiate an ER stress 
response,
DISCUSSION
Mutations in ELOVL4 cause Stargardt-like macular degen­
eration, an autosomal dominant juvenile macular degenera­
tion. The results of the present study suggested that ELOVL4 
aggregates may induce some toxicity at photoreceptor and/or 
RPE cellular levels, This mechanism may be directly exam­
ined in photoreceptors and the RPE in vivo using our ELOVL4 
transgenic mouse lines in future studies, Previous cell culture 
studies on the mutant ELOVL4 proteins have shown loss of 
ER localization, In this study, we found that mislocalization 
induced by the Stargardt causing ELOVL4 C-terminal m u­
tants, ELOVL4(5bp-del), and ELOVL4(270X), can be repro­
duced by substitution of a five-alanine tract for the ER reten­
tion domain. Thus, the primary effect of these mutations most 
likely arises from loss of the ER retention signal, These re­
sults are in agreement with a previous study [10] showing that 
a transfected ELOVL4 construct, with specific deletion of the
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Figure 4. Sucrose density gradient sedimentation and densitometric analysis of ELOVL4 aggregates. A: Western blots show immunolabeled 
wtEGFP/ELOVL4 and mutant ELOVL4 protein aggregates fractionated by sucrose density gradients. Cells were transfected with wtEGFP/ 
ELOVL4, mtEGFP/ELOVL4(5bp-del), or mtEGFP/ELOVL4(5A) or co-transfected with wtEGFP/ELOVL4 and mtEGFP/ELOVL4(5bp- 
del). wtEGFP/ELOVL4 signal was normally found in lower molecular weight fractions. The 5bp-del mutant and 5A mutant shifted to the 
lower fraction numbers indicating formation of larger molecular weight aggregates. M utant ELOVL4 (mtEGFP/ELOVL4(5bp-del)) induced 
the wild-type protein (wtEGFP/ELOVL4) to shift to the higher molecular weight fractions. Co-transfected cell lysates showed strong 
immunolabeling in higher molecular weight fractions similar to that of single-mutant transfections. B : Fractionated ELOVL4 proteins (wtEGFP/ 
ELOVL4, 5bp-del mutant, and 5A mutant) and co-transfected wtEGFP/ELOVL4 and mtEGFP/ELOVL4(5bp-del), measured by densitometry 
of western blots, are graphically represented.
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last five amino acids, KAKGD, similarly exhibits no ER re­
tention.
The role of ER stress in human pathogenesis has become 
a subject of great interest in the last few years. A growing 
number of neurodegenerative disorders such as Parkinson’s, 
Huntington’s, Alzheimer’s, and prion diseases have been linked 
to common pathological features arising from aggregate for-
Figure 5. ELOVL4 mutants induce UPR response proteins, CHOP 
and Bip. Cell lysates were collected 24 h post-transfection with wild- 
type or mutant ELOVL4 constructs. A: Samples from left to right 
include: vector alone, mtELOVL4(5A), mtELOVL4(5bp-del), and 
mtELOVL4(270X). B: CHOP protein levels were induced by trans­
fection of all ELOVL4 mutants, but not by overexpression of the 
wildtype ELOVL4 protein. C: Bip protein levels were similarly 
upregulated with mutant ELOVL4 expression. D: |3-actin used as a 
loading control. E: Tunicamycin control experiment showed CHOP 
upregulation. Lane 1: Untreated. Lane 2: Tunicamycin treated (10 
mg/ml). Lane 3: Tunicamycin treated (20 mg/ml).
mation and associated ER activation [24]. Protein aggregates 
in the form of neurofibrillary tangles, and cytoplasmic or 
nuclear inclusions induce the UPR, alter functional efficacy 
of the ubiquitin/proteasome system, and induce ER stress 
[18,25,26].
An important finding of this study is that all ELOVL4 
mutants inhibited wild-type ELOVL4 ER localization and re­
distributed the protein into aggregates. While expression of 
mutant ELOVL4 alone was sufficient for aggregate forma­
tion and induction of the UPR, corresponding mislocalization 
of the wild-type protein may have further consequences. 
Mislocalization may serve to inhibit the normal function of 
the wild-type protein, in essence, inducing a null ELOVL4 
phenotype. While these results revealed a possible dominant 
negative mechanism for mutant ELOVL4-induced cellular 
dysfunction, corresponding effects in photoreceptors and sub­
sequent consequences on the RPE need to be addressed. This 
may be directly examined in vivo using transgenic mice that 
express mutant ELOVL4 [15], and the mouse disease closely 
resembles human Stargardt macular degeneration.
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